Tyra Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
Tyra Biosciences, Inc. (TYRA), a Delaware corporation, filed this Current Report on Form 8-K on March 2, 2026. The filing serves to announce the company's financial results for the fiscal year ended December 31, 2025, via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1), which is incorporated by reference but not included in the text of this 8-K summary.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this filing. The document solely references the issuance of the annual results announcement.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that the information in this report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific revenue, net loss, and cash position figures for the year ended December 31, 2025.
- Verify the company's cash runway and burn rate as disclosed in the full annual results.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the status of the company's emerging growth company election and any related accounting standard transitions.